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Introduction: Immediate and acute stent recoil has been observed following balloon defla-
tion in normal and diseased coronary arteries, and the degree varies by stent design.
Methods: A total of 19 patients, who underwent elective stent implantation for single de novo
native coronary artery lesions, were enrolled: all patients treated with the biodegradable
polymer-coated sirolimus-eluting cobaltechromium coronary stent system (Supralimus-
Core). The immediate, acute and cumulative stent recoil was assessed by quantitative
coronary angiography. The cumulative stent recoil was measured at 24 h of stent
implantation.
Results: The absolute late loss due to recoil was found 0.08  0.19 mm for Immediate Stent
Recoil (ISR), 0.05  0.21 mm for Acute Stent Recoil (ASR) and 0.11  0.25 mm for Cumulative
Stent Recoil (CSR) respectively.
Conclusions: In vivo acute stent recoil of the Supralimus-Core has higher radial strength
compared to other available standard drug-eluting stents.
Copyright ª 2012, Cardiological Society of India. All rights reserved.1. Introduction forecaster of subsequent restenosis and probably clinicalIn Percutaneous Coronary Intervention (PCI), coronary stent
has been used as standard for treatment of Coronary Artery
Disease (CAD). They provide vessel wall scaffolding and
prevent early elastic recoil and restenosis as compared to
balloon angioplasty.1 The Geometric arterial remolding may
be a contributing factor to restenosis in human coronary
artery.2e4 Acute stent recoil reflects apparent inadequate stent
expansion and decreased final stent areawhich is a significantrformed: Shree B.D.M. Ma
4669.
; fax: þ91 261 2254669.
. Abhyankar).
2012, Cardiological Societevents.5 Drug-coated stents which use bioabsorbable polymer
may have more elastic recoil because polymers are more
elastic than metal.6 Acute recoil reduces the mean lumen
diameter immediately and it may be a contributor for late loss
of Minimal Luminal Diameter (MLD) and restenosis.7 It has
also been demonstrated that thin-strut CobalteChromium
(CoeCr) stents may lead to lower restenosis than thick strut
stainless steel stent. Minimum recoil should be an essential
property of an ideal stent. Low recoil (the ability of a stent tohavir Heart Institute, Athwagate, Ring Road, Surat 395001, Gujarat,
y of India. All rights reserved.
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to reduce the risk of subsequent malapposition or restenosis.
In the present study, we determined the acute recoil of the
vessel wall immediately and early after Supralimus-Core
Sirolimus-eluting stent system (Sahajanand Medical Tech-
nologies Pvt. Ltd., Surat, India) implantation.2. Materials and methods
This was a prospective, single-centre and non-randomized
study. A total 19 patients were enrolled and treated with 19
Supralimus-Core Sirolimus-eluting coronary stent systems
for de novo native coronary artery lesion. Patients with de novo
native coronary artery lesions located in epicardial vessel who
qualify for percutaneous coronary intervention were included
according to the pre-specified inclusion and exclusion criteria
for this study as mentioned below. Primary endpoint was
immediate and acute recoil following Supralimus-Core
Sirolimus-eluting coronary stent system implantation for de
novo native coronary artery lesions. This study was approved
by the local ethics committee and all patients gave written
informed consent.
During percutaneous coronary intervention procedure,
heparin boluses were intravenously administered and were
additionally given if needed. All study procedure for target
lesion were performed electively and treated using standard
interventional techniques, with mandatory pre-dilatation
with balloon size not less than 80% of reference vessel
diameter. The stent diameter was chosen nearly equal to
reference vessel diameter and not exceeding more than 15%
of reference vessel diameter. Stents were deployed at 15
atmospheres. Post-dilatation if required was performed with
balloon length less than stent length with pressure not
exceeding 16 atmospheres. Any patients requiring post-
dilatation using higher pressure or higher size balloon were
designed to be excluded.
2.1. Inclusion criteria
Patients included in the study were more than 18 years of age
with symptomatic ischemic heart disease with de novo
stenotic coronary lesion with Reference Vessel Diameter
(RVD) of 2.5 and 4.0 mm. Patient or patient’s legal repre-
sentative was informed of the nature of the study and agreed
to its provisions and had provided written informed consent
as notified/approved by the Institutional Review Board/Ethics
Committee of the clinical site.
This way all included patients had standard deployment
pressure of 15 atmospheres. All lesions were pre-dilated with
a balloon of same diameter. All stents were deployed using
a pressure of 15 atmospheres.
2.2. Exclusion criteria
Patients were excluded if any of the following conditions
were present: General exclusion criteria: 1) Women of child
bearing potential; 2) Acute or chronic renal dysfunction
(creatinine >2.0 mg/dl or >150 mmol/L); 3) Any patient who
has a platelet count <100,000 cells/mm3 or > 700,000 cells/mm3, a WBC of <3000 cells/mm3; 4) Evidence of an acute Q-
wave or non-Q-wave myocardial infarction within 72 h
preceding the index procedure; 5) Restenosis or significant
lesion in SVG. 6) Patient with a life expectancy less than 12
months; 7) Known allergies to aspirin, clopidogrel bisul-
phate (Plavix), ticlopidine (Ticlid), heparin or cobalte-
chromium; 8) Any significant medical condition which in
the investigator’s opinion may interfere with the patient’s
optimal participation in the study; 9) Currently partici-
pating in an investigational drug or another device study,
or subject to inclusion in another investigational drug or
another device study during follow-up; 10) Previous bare
metal stenting (less than 1 year) anywhere within the
target vessel or previous drug-eluting stenting anywhere
within any epicardial vessel.
Angiographic Exclusion criteria: 1) Unprotected left main
coronary artery disease with 50% stenosis; 2) Angiographic
evidence of thrombus 3) Ejection fraction 25%; 4) Heavily
calcified lesion and/or calcified lesion which cannot be
successfully pre-dilated.
2.3. Description of the study stent
Supralimus-Core (Sahajanand Medical Technologies Pvt.
Ltd., Surat, India) has L605 CoeCr alloy as its stent platform
having strut thickness of 60 mm with biodegradable poly-
mers and drug load of 1.4 mg/mm2. About 70% of drug is
released within 7 days and remaining drug is released over
a period of 48 days. The coating layer comprises of drug
Sirolimus blended together with biodegradable polymeric
matrix. This matrix includes different biodegradable poly-
mers e poly L-lactide, 50/50 poly DL-lactide-co-glycolide and
polyvinylpyrrolidone to control the drug elution from stent
coating. After releasing the drug within 48 days, these
polymers eventually degrade naturally and are excreted
from the body in the form of their metabolites. The average
coating thickness of Supralimus-Core stent is between 5
and 6 mm.
2.4. Interventional procedure and adjunctive
medications
All patients were on aspirin in a dose of 75e150 mg at least
24 h prior to the procedure. A loading dose of 300 mg of clo-
pidogrel was given 24 h prior to procedure or 600 mg on the
day of the procedure was given to patients before procedure.
During the procedure initial dose of 100 IU/kg bolus of heparin
was given to the patient. Additional heparin was used if
necessary during procedure to achieve activated coagulation
time >250 s. Administration of GP IIb/IIIa inhibitor was left to
the investigator’s discretion.
Pre-procedural pictures were recorded into two orthog-
onal views. After pre-dilating lesion stent was deployed at
15 atmospheres and a picture of inflated balloon was
recorded in two angiographic views. Immediately after stent
deployment and after last balloon dilatation angiographic
pictures were recorded in two orthogonal views similar to
pre-dilatation angiograms. Angiography was performed at
24 h after the stent procedure and pictures were recorded in
similar orthogonal views.
Table 1 e Baseline demographics data (n[ 19).
Patient characteristics
Age (mean  SD, years) 57.3  9.9
Male, n (%) 15 (78.9%)
Diabetes mellitus, n (%) 11 (57.9%)
Hypertension, n (%) 12 (63.2%)
Dyslipidemia, n (%) 16 (84.2%)
Smoking, n (%) 1 (5.3%)
Prior myocardial infarction n (%) 1 (5.3%)
Unstable angina, n (%) 19 (100%)
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QCA was performed using CAAS V analysis system (Pie
Medical BV, Maastricht, the Netherlands). The following QCA
parameters were computed: Minimal Luminal Diameter
(MLD), Reference Vessel Diameter (RVD), and percent diam-
eter stenosis for pre, immediate post-procedure and 24 h
angiogram. Balloon diameter was measured on the inflated
balloon picture. Immediate, acute and cumulative stent recoil
was calculated by following formula (Fig. 1):
1) Immediate Stent Recoil (ISR): immediate stent recoil was
defined as expanded stent mean lumen diameter during
balloon inflation (A) minus stent mean lumen diameter at
immediate angiography after balloon deflation (B).
Percent immediate stent recoil was defined as (A  B)/
A  100
2) Acute Stent Recoil (ASR): acute stent recoil was defined as
stent mean lumen diameter at immediate angiography
after balloon deflation (B) minus stent lumen diameter at
24hr after angiography (C). Percent acute stent recoil was
defined as (B  C)/B  100
3) Cumulative Stent Recoil (CSR): cumulative stent recoil was
defined as expanded stent lumen diameter during balloon
inflation (A) minus stent lumen diameter at 24 h angiog-
raphy (C). Percent cumulative stent recoil was defined as
(A  C)/A  100.
2.6. Statistical analysis
Discrete variables are expressed as counts and percentages
and were compared in terms of relative risks with 95% confi-
dence intervals. Count variables were summarized by the
count and the percentage. Continuous variables are expressed
as means  SD. The normality of the distributions of mean
acute recoil after deflation of balloon was tested with Sha-
piroeWilk test.Fig. 1 e Immediate, acute and cumulative stent recoil.3. Results
3.1. Baseline patient characteristics and follow-up
The baseline demographics, procedural and lesion charac-
teristics of the Supralimus-Core recoil study population have
been summarized (Tables 1 and 2).3.2. Angiographic and clinical outcomes
Total 19 patients (19 lesions) were implanted with 19 stents
with average lesion length of 10.68  3.16 mm. All angiograms
were evaluated by readers blinded to the study stent, by an
independent core laboratory (Zeus Data Power LLP). Using the
formula as stated above the ISR, ASR and CSRwere found to be
2.42  7.48%, 1.12  7.24% and 3.24  8.27% respectively.
Twenty four hours angiographic follow-up was performed in
all 19 patients (Table 3). As shown in Tables 4 and 5, acute and
cumulative stent recoil was calculated during mean diameter
of balloon at the highest pressure, mean diameter of stent
immediately after balloon deflation and mean diameter of
stent at 24 h follow-up (Fig. 2).
The absolute late loss due to recoil was found
0.08  0.19 mm for ISR, 0.05  0.21 mm for ASR and
0.11  0.25 mm for CSR respectively.
The normality of the distributions of mean acute recoil
after deflation of balloon was tested with ShapiroeWilk test
( p ¼ 0.001) and left skewness (2.083) (Fig. 3).
We tried to establish the correlation of certain variables
with the stent recoil. We studied the relationship of referenceTable 2 e Lesion and procedural characteristics (n[ 19).
Lesion location
Right coronary artery, n (%) 10 (52.6%)
Left circumflex, n (%) 1 (5.3%)
Left anterior descending, n (%) 8 (42.1%)
Lesion type (ACC/AHA)
A, n (%) 1 (5.3%)
B1, n (%) 4 (21.1%)
B2, n (%) 10 (52.6%)
C, n (%) 4 (21.1%)
Stent to artery ratio 0.92  0.12
Average lesion length, mm 10.68  3.16
Clinical success 19 (100%)
ACC ¼ American College of Cardiology; AHA ¼ American Heart
Association.
Table 3 e Quantitative coronary angiographic analysis
(n[ 19).
QCA parameters Mean  SD
Pre-PCI n[ 19
Lesion length, mm 10.68  3.16
Reference vessel diameter, mm 2.61  0.44
Minimum lumen diameter, mm 1.11  0.32
Diameter stenosis, % 55.84  15.87
Post-PCI n[ 19
Minimum lumen diameter, mm 2.37  0.36
Diameter stenosis, % 13.32  4.47
Acute gain, mm 1.26  0.54
Follow-up PCI (24 h) n[ 19
Minimum lumen diameter, mm 2.30  0.34
Diameter stenosis, % 16.13  5.85
Late loss, mm 0.04  0.10
Table 5 e Stent recoil (n[ 19).
Mean lumen diameter
Mean  SD
(mm) %
Mean stent expansion minus mean
post-stent expansion, (mm)
(immediate stent recoil)
0.08  0.19 2.42  7.48
Mean post-stent expansion minus
mean follow-up stent expansion,
(mm) (acute stent recoil)
0.05  0.21 1.12  7.24
Mean stent expansion minus mean
follow-up stent expansion, (mm)
(cumulative stent recoil)
0.11  0.25 3.24  8.27
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using Pearson correlation coefficient. The relationship of
reference vessel diameter and lesion length is shown in Figs. 4
and 5. The figures show that there is no strong positive
correlation between reference vessel diameter with imme-
diate recoil and very weak positive correlation between lesion
lengths with immediate recoil.
We also tried to study the possible effect of diabetes
mellitus on recoil as diabetes could affect the elastic property
of vessel wall. In our study there were 11 (57.9%) diabetics.
The comparison of diabetics and non-diabetics was done
using ManneWhitney U test which is depicted graphically in
Fig. 6.
There are no in-hospital events and stent thrombosis
events reported. No clinical events reported at 6 months.4. Discussion
The main function of metallic stents is to scaffold the vessel
wall and prevent early elastic recoil and acute vessel closure.8
Minimum stent recoil is a desirable property of a stent since
stent recoil can contribute to reduced acute gain of MLD and
possible contribute to higher late loss of lumen.
Despite advances in polymer and drug technology, the
underlying stent platform remains a key determinant of
clinical outcome. Reduction in stent strut thickness has been
associated with improved stent deliverability, improved
procedural outcome, and lower rates of subsequentTable 4 e Angiographic parameters related with acute
stent recoil assessments (n [ 19).
Angiographic parameters Mean  SD (mm)
Mean diameter of balloon/stent
at the highest pressure (mm)
2.81  0.41
Mean diameter of stent immediately
after balloon deflation (mm)
2.73  0.37
Immediate stent recoil (mm) 0.08  0.19
Immediate percent recoil (%) 2.42  7.48restenosis. Newer-generation 316L-SS stent designs have
enabled reduced strut thickness while retaining radial
strength and minimizing recoil. Cobaltechromium alloys
have enabled a reduction in stent strut thickness to around
60e90 mm while retaining modest radiopacity, but due to
higher elastic properties, have been possibly associated with
greater stent recoil.9
In previous human clinical trials, acute stent recoil varied
between 3% and 15% followingWiktor or PalmazeSchatz stent
implantation.10e13 Stent recoil was usually defined as the
difference between the minimum balloon diameter and the
MLD post-stent implantation. However, usage of minimum
variables, proposed by previous investigators, has the poten-
tial for assessing only a part of the stented segment, because
the balloon does not expand uniformly, causing asymmetric
stent expansion. To reflect the behavior of the vessel wall of
the entire stented segment, we used mean variables and
defined acute stent recoil as the difference between the mean
diameter of the last inflated balloon and the mean luminal
diameter immediately after the last balloon deflation. Our
study demonstrated that the immediate stent recoil of the
Supralimus-Corewas 0.08  0.19 mm (2.42%), which is lower
than previously reported in vivo conventional metallic stent
recoil.
The CSR for Supralimus-Core stent was 3.24  8.27%. This
is lower compared to most available cobaltechromium stents.
This is likely to contribute to better long-term results using
Supralimus-Core stents. However this needs to be estab-
lished by studying actual clinical and angiographic outcomes.Fig. 2 e Sequential measurements of minimal luminal
diameter of pre-PCI, stent expansion, post-stent expansion
and follow-up (each line represents the data from a single
patient).
Fig. 3 e Normality distribution of mean acute recoil. Fig. 5 e Reference vessel diameter vs. immediate recoil.
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shown in Fig. 7. Unlike previous studies we studied the
immediate, acute and cumulative stent recoil separately. The
results bring out very interesting observation that the acute
stent recoil (additional recoil at 24 h after immediate recoil)
contributed minimally to the cumulative stent recoil and
immediate stent recoil reflected most of the total recoil. This
has a very important bearing for the future studies of this
nature as it obviates the need for 24 h angiogram.
We studied the effects of reference vessel diameter and
lesion length and found that they have no bearing on the
recoil. This suggests that the recoil is probably not affected
whether the vessel is large or small in diameter (Figs. 4 and 5).
The figures show that there is no strong positive correlation
between reference vessel diameter with immediate recoil
and very weak positive correlation between lesion lengths
with immediate recoil. This however needs to be established
in larger numbers as it may have a bearing on future stent
designing.Fig. 4 e Lesion length vs. immediate recoil.
Fig. 6 e Recoil box plot in diabetic and non-diabetic
patients.
Fig. 7 e Recoil comparisons across current stent platforms.
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revealed that presence of diabetes did not impact the recoil.
However the small size of this study limits drawing hard
conclusions in this regard but opens up interesting probabil-
ities of exploring these aspects further.
The ISR, ASR and CSR of Supralimus-Core were
2.42 7.48%, 1.12 7.24% and 3.24 8.27% respectively, which
is comparable to or lower than recoil of most CoeCr DES.
Stent recoil was not affected by vessel diameter or lesion
length.5. Conclusions
In vivo acute stent recoil of the Supralimus-Core has higher
radial strength compared to other available standard drug-
eluting stent.Funding
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